ForbionBritish company Sitala Bio Ltd, founded in 2021 by NLRP3 inflammasome expert Matt Cooper, is paying US$670m and giving up to 10% of its shares to Chinese company Shanghai Fosun Pharmaceutical Group Co. Ltd. in exchange for the development and marketing rights to the low-molecular-weight inflammation blocker FXS6837.
Adobe stock photos - JimEli Lilly, the US market leader in the lucrative diabetes and obesity space, is now challenging its competitor Novo Nordisk in the area of oral GLP-1 receptor agonists. Lilly’s orforglipron has met the primary endpoint of its registration study and is set to be submitted for approval in the United States.
Calluna Pharma A/SNorway-based Calluna Pharma A/S has initiated patient recruitment in late August for its Phase II AURORA trial investigating safety and efficacy of CAL101, a monoclonal antibody with unique mode of action to cure idiopathic pulmonary fibrosis.
BioArctic ABFollowing the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company access to BioArctic’s BrainTransporter platform to transport therapeutics for neurodegeneration across the blood-brain barrier
Esai PharmaSwedish BioArctic AB’s partner Eisai Pharma has started the European roll-out of their Alzheimer’s antibody lecanemab in Austria that will be followed by the German launch on September 1, 2025.
POWTECH TECHNOPHARM (Nuremberg, 23-25 September 2025) is the international trade fair for process engineering experts and a tailor-made technology platform for the pharmaceutical and life science industries.
EFPIAThe US and EU have confirmed a trade agreement involving US import tariffs of 15% on prescription medicines. Generics manufacturers will face a maximum tariff of 2.5%.
AlzeCure Pharma ABSwedish AlzeCure Pharma AB recently appointed Cecilia Wadell as Head of Development. She joins also the management team.
MalliaGermany’s Mallia Aesthetics GmbH has announced the achievement of key regulatory milestones in preparation for the market launch of its sCD83-based hair growth stimulant, MAL-838, later this year.
Sino BiologicalChikungunya virus (CHIKV) is a mosquito-borne alphavirus causing fever, severe joint pain, rash, and muscle aches, mainly transmitted by Aedes mosquitoes. The outbreak began on islands in the Indian Ocean and had spread to 119 countries by 2025, including temperate regions such as France. Key control strategies include vector control, surveillance, health system preparedness, and international cooperation. Sino Biological supports research by providing recombinant CHIKV antigens and antibodies, which are useful for vaccines, antiviral drugs, and diagnostics.